Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Ascendis Pharma (ASND) Revenue Nearly Doubles to 720M in 2025 Fueled by Core Product Growth

Ascendis Pharma (ASND) Revenue Nearly Doubles to 720M in 2025 Fueled by Core Product Growth

FinvizFinviz2026/02/20 09:12
By:Finviz

Ascendis Pharma (NASDAQ:ASND) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 11, Ascendis Pharma reported that it nearly doubled its total revenue for 2025 to €720 million, fueled by the rapid global adoption of its core endocrinology products. Q4 was particularly significant, as the company achieved an operating profit of €10 million and generated €73 million in operating cash flow. This was largely driven by YORVIPATH, which brought in €477 million for the full year, and the steady performance of SKYTROFA, which contributed €206 million.

Despite a full-year net loss of €228 million due to commercial investments, the company ended the year with a solid cash position of €616 million, supported by a $100 million partnership payment from Novo Nordisk. The company’s success is rooted in its proprietary TransCon tech platform, which transforms established drugs into long-acting, once-weekly prodrugs. By linking parent drugs to an inert carrier via a temporary linker, TransCon ensures a predictable and sustained release of the active medication.

Ascendis Pharma (ASND) Revenue Nearly Doubles to 720M in 2025 Fueled by Core Product Growth image 0
15 States with the Best Healthcare in the US

This has allowed Ascendis Pharma (NASDAQ:ASND) to secure a dominant 45% share of the US long-acting growth hormone market for SKYTROFA. Management is now preparing for the next major growth phase with the anticipated FDA approval of TransCon CNP for pediatric achondroplasia, which has a PDUFA action date of February 28, 2026, and is expected to provide a new therapeutic option beyond simple linear growth.

Ascendis Pharma (NASDAQ:ASND) is a biopharmaceutical company that develops TransCon-based (Transient Conjugation) therapies for unmet medical needs in Europe, the US, and internationally.

READ NEXT:
 and
.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!